S. Hautaniemi

Multi-Omics Analysis Reveals the Attenuation of the Interferon Pathway as a Driver of Chemo-Refractory Ovarian Cancer

The paper identifies reduced IFN-I pathway activity as a driver of chemo-refractory ovarian cancer using multi-omics analysis in a clinical trial cohort.

Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer

This study shows chemotherapy causes myeloid-driven spatial T-cell exhaustion in ovarian cancer by altering immune cell states and interactions, suggesting new immunotherapy approaches.

Patient-derived functional immuno-oncology platform identifies responders to ATR inhibitor and immunotherapy combinations in ovarian cancer

Direct conversion of human fibroblasts to pancreatic epithelial cells through transient progenitor states is controlled by temporal activation of defined factors

This study reprograms human fibroblasts to pancreatic exocrine cells using six transcription factors and identifies transient progenitor states as key intermediates in the process.

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cells

This study identifies CK2 inhibition as a sensitizing strategy for RB1-deficient ovarian and breast cancer cells to replication-perturbing drugs, showing enhanced efficacy when combined with existing therapies.

Lineage-specific oncogenes drive growth of major forms of human cancer using common downstream mechanisms

The paper identifies common downstream mechanisms driven by lineage-specific oncogenes that regulate cell proliferation in various cancers.

L1 retrotransposition is regulated post-transcriptionally In High-Grade Serous Ovarian Cancer

The paper investigates L1 retrotransposition in HGSC, finding that despite high L1 mRNA expression, only a third of tumors show somatic insertions, with variability in retrotransposition frequency and patterns.

Evolutionary states and trajectories characterized by distinct pathways stratify ovarian high-grade serous carcinoma patients

This study identifies three evolutionary states of ovarian high-grade serous carcinoma using whole-genome sequencing and links them to distinct therapeutic targets.

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids

This paper describes a method to generate and expand high-grade serous ovarian cancer organoids with improved success rates and reports their drug response correlation with clinical outcomes.

Optimized detection of allelic imbalances specific for homologous recombination deficiency improves the prediction of clinical outcomes in cancer

The paper develops a tumor-specific method to detect allelic imbalances for HRD prediction, showing improved clinical outcome prediction in ovarian and breast cancers.

Epigenetic inhibitors sensitize DLBCL cells to rituximab and doxorubicin

This study identifies epigenetic inhibitors that enhance the effectiveness of immunochemotherapy in DLBCL by disrupting DNA repair and cell cycle pathways.